In 2020, the DNBSEQ-T7 Gene Sequencer of Wuhan MGI Technology Co., Ltd. (hereinafter referred to as “MGI”) was approved (Registration No.: G.X.Z.Z. 20,203,220,061).

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

The global POC blood glucose monitoring devices market is expected toreach USD 2.03 billion in 2022, driven mainly by public and private initiativesto reduce diabetic cases. However, the high cost associated with diabetesmanagement is one o

MA activity in the liquid biopsy space is picking up as Bio-Techne said it will acquire Exosome Diagnostics for $250 million plus $325 million in potential milestones. Waltham, MA-based Exosome has developed the urine-based test ExoDx Prost

President Donald Trump is trying to shame the largest U.S. drugmaker for hikingpricesafter he earlier said industry players were planning massive price reductions. He said Pfizer and others should be ashamed that they have raised drug price

The global molecular diagnostics market is expected to grow at a CAGR of8.4% from USD 7.71 billion in 2018 to USD 11.54 billion by 2023, driven by theincreasing prevalence of infectious diseases and various types of cancers,rising awareness

Video-assisted lobectomies performed withpowered staplers resulted in nearly half as many patient bleeding complicationsas those conducted with manual staplers, according to a recent study. Patients treated with powered staplers wererelease

Medtronic topped estimates in its latestearnings, fueled by sales from valves and diabetes products. For theDublin-based companys 4Q18 earnings it brought in about $8.14 billion, a 6.5percent increase. The firms Cardiac and Vascular group (

The National Institutes of Healths All ofUs Research Program issued a funding announcement today for Genome Centers togenerate genotype and whole-genome sequence data from the samples submitted byparticipants in the program. The information

The Association of Community Cancer Centers(ACCC), a cancer care provider advocacy group, announced today that Pfizer willprovide $1.5 million in grant funding to support initiatives integrating BRCAtesting into patient care plans.

​ 绿叶生命科学集团旗下Vela Diagnostics表示，中国食品药物监督管理总局已批准其Sentosa SX游离DNA试剂盒。 该试剂盒旨在从血浆中提取血浆游离循环DNA，并开发用于RT-PCR和第二代基因测序